Abstract: Protein undernutrition is frequent in the elderly. It contributes to the development of osteoporosis, possibly via lower IGF-I. Dietary zinc can influence IGF-I production. Objectives: To determine the influence of dietary zinc addition on IGF-I and bone turnover responses to essential amino acids-whey (EAA-W) protein supplements in frail elderly. Design and setting: A daily oral protein supplement was given to hospitalized patients for 4 weeks. On a randomized, double-blind basis, patients received either an additional 30 mg/day of zinc or control. Participants: Sixty-one hospitalized elderly aged 66.7 to 105.8, with a mini-nutritional assessment score between 17 and 24 were enrolled. Measurements: Activities of daily living; dietary intakes; serum IGF-I, IGF-BP3, CrossLaps TM , osteocalcin and zinc were measured before and after 1, 2 and 4 weeks of protein supplementation. Results: Serum IGF-I rapidly increased in both groups. Zinc accelerated this increase with changes of +48.2±14.3 and +22.4±4.7% (p<.05) by 1 week, in the zinc-supplemented and control groups, respectively. Zinc significantly decreased the serum bone resorption marker CrossLaps TM by already 1 week. Activities of daily living improved by +27.0±3.1 and +18.3±4.5% in zinc-supplemented and control groups, respectively.Conclusion: In the elderly, zinc supplementation accelerated the serum IGF-I response to EAA-W protein by 1 week and decreased a biochemical marker of bone resorption.
Introduction
Undernutrition, particularly protein deficiency, is often encountered in the elderly population (1, 2). Whilst a reduction in caloric intake may accompany the decrease in energy expenditure in the elderly, it appears that sufficient protein intakes are mandatory for bone health (3). A concurrent reduction of dietary protein with aging could be detrimental for the preservation of bone integrity. A variety of cross-sectional and longitudinal studies have shown a positive association between bone mineral mass and dietary protein intake (4-8). Dietary proteins influence both the production and action of IGF-I and thereby the effect of IGF-I on bone anabolism (3, 9, 10) . In preclinical studies, an isocaloric low protein diet decreases areal bone mineral density (BMD) at the levels of skeletal sites formed by trabecular and cortical bone (11, 12), alters trabecular microarchitecture, renders bone cortices thinner (13) and modifies intrinsic bone tissue quality as evaluated by a nanoindentation test (14) . These various changes result in a decrease of bone strength. In humans, these alterations could contribute to an increased fracture risk (3, 15) .
In terms of molecular mechanisms, an isocaloric low protein diet is associated with increased bone resorption and decreased bone formation, reduced IGF-I production, and an accompanying resistance of bone to the effects of both IGF-I and growth hormone (16, 17) . An altered gonadotrop axis in both males and females has also been documented (11, 12) . The bone catabolic effects of an isocaloric low protein diet seem to be a TNF-alpha-dependent process (18).
Protein repletion corrects the alterations caused by protein undernutrition. Indeed, in elderly patients with a recent hip fracture, protein supplements decrease the rates of medical complications (19, 20) , reduce accelerated bone loss (21, 22) , and lower the duration of stay in rehabilitation care facilities by 25% (21). These observations have been associated with an increase in circulating serum IGF-I levels. In preclinical studies, isocaloric essential amino acid supplements correct bone mechanical properties by improving microarchitecture (connectivity and cortical thickness), and intrinsic bone tissue quality (13, 14) . The correction of protein deficiency also reverses the alterations in both the somatotrop and gonadotrop axes, and in bone remodeling.
Zinc is known to play a role in IGF-I production (23, 24). Circulating levels of IGF-I increase with dietary zinc supplementation (25, 26) . Growth retardation related to zinc deficiency is associated with low serum IGF-I concentrations, inhibition of the anabolic actions of IGF-I (27) and with a decreased expression of the IGF-I and GH receptor genes (27, 28) . A meta-analysis of 25 studies investigating the effects of zinc supplementation on growth in prepubertal children showed a highly statistically significant effect on linear growth and weight gain (29). On the other hand, decreased zinc reserves are observed in undernourished subjects (30, 31) . The presence of zinc inhibits the stimulatory effect of regucalcin, a regulatory protein involved in intracellular signalling on osteoclast-like cell formation (32). Several studies have shown that zinc has a distinct effect on bone metabolism by inhibiting bone resorption and stimulating bone formation (32-36). The relationship between zinc status and IGF-I in the elderly has not been established, although the correlation between serum IGF-I concentrations and zinc intake was significantly better than that with protein intake or age in a group of healthy community-dwelling post-menopausal women (24).
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ZINC INCREASES THE EFFECTS OF ESSENTIAL AMINO ACIDS-WHEY PROTEIN SUPPLEMENTS IN FRAIL ELDERLY
In the present study, we assessed the effect of zinc supplements on circulating IGF-I levels, bone remodeling and physical performance responses to protein repletion in undernourished, elderly patients. The results indicate that zinc supplementation accelerates the serum IGF-I response to essential amino acids-whey protein administration, and is associated with a decrease in the serum levels of a biochemical marker of bone resorption and improved functional performance.
Patients and methods
Patients
Within one week after admission to a tertiary care geriatric hospital, elderly patients of both sexes were recruited between October 1999 and August 2001. Admissions were due to cardiovascular and lung diseases (27%), osteoarticular disorders (16%), infections (13%), neurological diseases (10%), falls, psychiatric disorders or skin diseases (34%). Inclusion criteria consisted of ability to give a written, informed consent and a mini nutritional assessment score between 17 and 24 (corresponding to a failure to thrive category) (37). Exclusion criteria were: severely decompensated cardiac, pulmonary, renal (creatinine clearance <30 ml/min) or hepatic failure; major mental impairment (minimal mental state score <17), urine incontinence, inflammatory syndrom (C-reactive protein >15mg/l), bedridden, corticosteroids at a dose greater than 7.5 mg/day prednisone-equivalent, life expectancy estimated as shorter than one month. All patients were given a daily 20 g oral protein supplement containing 15g whey protein and 5g essential amino acids (in a proportion similar to that found in casein), and 550mg calcium (provided by Novartis Nutrition, Berne, Switzerland). The protein supplement was administered in the evening preferentially, or fractionated throughout the day, for a period of 4 weeks. Using a random number table, the patients were assigned to 30mg/day oral zinc directly added to the protein supplements powder, or no addition, on a strict double-blind basis. Non compliance was defined by consumption of less than 50% of the powder. The patients were stratified into two arms according to baseline serum albumin levels, with a limit between strates of 30 g/l in a fully hydrated state. A group of 8 patients fulfilling the same inclusion and exclusion criteria, but who did not want to participate in an intervention study, were followed at a 4-week interval.
Clinical data
We evaluated clinical status, dietary intakes, activities of daily living (38) and medical treatments at baseline (within one week after admission), and after 1, 2 and 4 weeks of nutritional supplementation. Compliance, incidence of medical complications and side effects of treatment (diarrhea, nausea), and length of hospital stay were recorded.
Biochemical analysis
Fasting venous blood and second voiding urine samples were collected at baseline, and after 1, 2 and 4 weeks of nutritional supplements. Radioimmunoassays, immunoradiometric assays and enzyme-linked immunoassay were used to measure calcidiol (Incstar Corp, Stillwater, MN), intact parathormone (Nichols institute, San Juan Capistrano, CA), IGF-I after acid-ethanol extraction (Nichols institute, San Juan Capistrano, CA), IGF-binding protein-3 (DSL, Webster, Texas), osteocalcin (Cis-Bio, Gif-sur-Yvette, France), and CrossLaps TM (Roche-diagnostic, Lucerne, Switzerland). Calcitriol was determined using a protein-binding assay (Incstar Corp, Stillwater, MN) . Albumin, protein, total calcium, phosphate, creatinine and C-reactive protein were measured using routine laboratory methods. Ionized calcium was measured using a specific electrode. Zinc was determined using the Randox colorimetric method (automate COBAS INTEGRA 700, Roche-diagnostic). Differential white cell counts were determined at weeks 0, 1, 2, and 4. Renal tubular transports of calcium and phosphate were measured with fasting serum and urine values, using nomograms as previously described (39, 40) .
Statistical analysis
Values are means ± SEM. Level of significance was evaluated using an unpaired two-tailed student t-test, when two groups were compared, an ANOVA for repeated measurements was used to evaluate evolution over time and a Wilcoxon rank test was employed as an alternative to the paired student t-test to compare two groups, when the values were not normally distributed.
Results
Trial outline
We recruited 61 patients into this randomized, double-blind trial and 8 untreated controls. During the 28-day intervention period, 14 (23%) patients dropped out, 12 due to nausea, low compliance, refusal to pursue the trial at home and 2 deaths (one at home from bronchopneumonia and one in hospital from bronchoaspiration). For the final analysis, 47 patients and 5 untreated controls were available (Fig.1) . Twenty-seven patients returned home before the end of the study. Blood and urine samples were collected in their private accommodation.
Baseline characteristics 85% of enrolled patients were women and the mean age was 85.0 ± 7.4 years (mean ± SD, range: 66.7 to 105.8). The different diagnoses were equally distributed in both groups (data not shown). Baseline characteristics were similar in the randomized groups (Table 1 ). Dietary energy intake was 1228 ± 7.0 Kcal/day (5140 KJ) with 43 ± 3 g/day protein,
